REPL
Replimune Group Inc
NASDAQ: REPL · HEALTHCARE · BIOTECHNOLOGY
$16.06
+23.07% today
Updated 2026-10-28
Market cap
$1.17B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.15
Dividend yield
—
52W range
$2 – $16
Volume
2.3M
Replimune Group Inc (REPL) Insider transactions
Net insider activity
Net buying (3,677,685 shares)
Buy transactions
62
Sell transactions
38
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-01 | SARCHI, CHRISTOPHER | Chief Commercial Officer | Sale | 12,000 | $9.24 | $110880.00 |
| 2026-05-18 | XYNOS, KONSTANTINOS | Chief Medical Officer | Sale | 14,023 | $5.08 | $71236.84 |
| 2026-05-18 | SCHWENDENMAN, ANDREW | Chief Accounting Officer | Sale | 7,894 | $5.08 | $40101.52 |
| 2026-05-18 | SARCHI, CHRISTOPHER | Chief Commercial Officer | Sale | 8,626 | $5.08 | $43820.08 |
| 2026-05-18 | PATEL, SUSHIL | Director, Chief Executive Officer | Sale | 37,324 | $5.08 | $189605.92 |
| 2026-05-18 | HILL, EMILY LUISA | Chief Financial Officer | Sale | 7,812 | $5.08 | $39684.96 |
| 2026-05-18 | ASTLEY-SPARKE, PHILIP | Director | Sale | 17,657 | $5.08 | $89697.56 |
| 2026-04-02 | SARCHI, CHRISTOPHER | Chief Commercial Officer | Sale | 6,500 | $8.01 | $52065.00 |
| 2026-04-01 | XYNOS, KONSTANTINOS | Chief Medical Officer | Buy | 75,000 | — | — |
| 2026-04-01 | XYNOS, KONSTANTINOS | Chief Medical Officer | Buy | 50,000 | — | — |
| 2026-04-01 | WEINAND, DIETER | Director | Buy | 44,500 | — | — |
| 2026-04-01 | SLATTERY, JOSEPH P | Director | Buy | 44,500 | — | — |
| 2026-04-01 | SCHWENDENMAN, ANDREW | Chief Accounting Officer | Buy | 55,000 | — | — |
| 2026-04-01 | SCHWENDENMAN, ANDREW | Chief Accounting Officer | Sale | 36,667 | — | — |
| 2026-04-01 | SARCHI, CHRISTOPHER | Chief Commercial Officer | Buy | 75,000 | — | — |
| 2026-04-01 | SARCHI, CHRISTOPHER | Chief Commercial Officer | Buy | 50,000 | — | — |
| 2026-04-01 | PUCCI, PAOLO | Director | Buy | 44,500 | — | — |
| 2026-04-01 | PEEPLES-DYER, VELEKA | Director | Buy | 44,500 | — | — |
| 2026-04-01 | PATEL, SUSHIL | Director, Chief Executive Officer | Buy | 376,860 | — | — |
| 2026-04-01 | PATEL, SUSHIL | Director, Chief Executive Officer | Buy | 251,240 | — | — |
| 2026-04-01 | OLIGER, CHRISTY J. | Director | Buy | 44,500 | — | — |
| 2026-04-01 | HILL, EMILY LUISA | Chief Financial Officer | Buy | 75,000 | — | — |
| 2026-04-01 | HILL, EMILY LUISA | Chief Financial Officer | Buy | 50,000 | — | — |
| 2026-04-01 | DHINGRA, KAPIL | Director | Buy | 44,500 | — | — |
| 2026-04-01 | BALACHANDRAN, MADHAVAN | Director | Buy | 44,500 | — | — |
| 2026-04-01 | BAKER, BROS. ADVISORS LP | Director, 10% Owner | Buy | 44,500 | — | — |
| 2026-04-01 | ASTLEY-SPARKE, PHILIP | Director | Buy | 75,000 | — | — |
| 2026-04-01 | ASTLEY-SPARKE, PHILIP | Director | Buy | 50,000 | — | — |
| 2026-02-18 | ASTLEY-SPARKE, PHILIP | Director | Sale | 25,000 | — | — |
| 2025-12-19 | XYNOS, KONSTANTINOS | Chief Medical Officer | Buy | 60,000 | — | — |
| 2025-12-19 | SCHWENDENMAN, ANDREW | Chief Accounting Officer | Buy | 10,000 | — | — |
| 2025-12-19 | SARCHI, CHRISTOPHER | Chief Commercial Officer | Buy | 35,000 | — | — |
| 2025-12-19 | PATEL, SUSHIL | Director, Chief Executive Officer | Buy | 200,000 | — | — |
| 2025-12-19 | HILL, EMILY LUISA | Chief Financial Officer | Buy | 60,000 | — | — |
| 2025-12-09 | DHINGRA, KAPIL | Director | Sale | 3,169 | — | — |
| 2025-12-09 | DHINGRA, KAPIL | Director | Buy | 3,169 | $1.75 | $5545.75 |
| 2025-12-02 | PATEL, SUSHIL | Director, Chief Executive Officer | Sale | 10,000 | $11.13 | $111300.00 |
| 2025-11-17 | XYNOS, KONSTANTINOS | Chief Medical Officer | Sale | 7,248 | $9.10 | $65956.80 |
| 2025-11-17 | SARCHI, CHRISTOPHER | Chief Commercial Officer | Sale | 5,208 | $9.10 | $47392.80 |
| 2025-08-15 | HILL, EMILY LUISA | Chief Financial Officer | Sale | 9,154 | $5.37 | $49156.98 |
| 2025-05-20 | XYNOS, KONSTANTINOS | Chief Medical Officer | Sale | 7,952 | $8.06 | $64093.12 |
| 2025-05-20 | SCHWENDENMAN, ANDREW | Chief Accounting Officer | Sale | 3,287 | $8.05 | $26460.35 |
| 2025-05-20 | SARCHI, CHRISTOPHER | Chief Commercial Officer | Sale | 3,749 | $8.05 | $30179.45 |
| 2025-05-20 | PATEL, SUSHIL | Director, Chief Executive Officer | Sale | 25,105 | $8.06 | $202346.30 |
| 2025-05-20 | HILL, EMILY LUISA | Chief Financial Officer | Sale | 2,535 | $8.05 | $20406.75 |
| 2025-05-20 | ASTLEY-SPARKE, PHILIP | Director | Sale | 32,279 | $8.06 | $260168.74 |
| 2025-04-01 | XYNOS, KONSTANTINOS | Chief Medical Officer | Buy | 67,500 | — | — |
| 2025-04-01 | XYNOS, KONSTANTINOS | Chief Medical Officer | Buy | 45,000 | — | — |
| 2025-04-01 | WEINAND, DIETER | Director | Buy | 32,000 | — | — |
| 2025-04-01 | SLATTERY, JOSEPH P | Director | Buy | 32,000 | — | — |
| 2025-04-01 | SCHWENDENMAN, ANDREW | Chief Accounting Officer | Buy | 50,000 | — | — |
| 2025-04-01 | SCHWENDENMAN, ANDREW | Chief Accounting Officer | Sale | 33,333 | — | — |
| 2025-04-01 | SARCHI, CHRISTOPHER | Chief Commercial Officer | Buy | 67,500 | — | — |
| 2025-04-01 | SARCHI, CHRISTOPHER | Chief Commercial Officer | Buy | 45,000 | — | — |
| 2025-04-01 | PUCCI, PAOLO | Director | Buy | 32,000 | — | — |
| 2025-04-01 | PEEPLES-DYER, VELEKA | Director | Buy | 32,000 | — | — |
| 2025-04-01 | PATEL, SUSHIL | Director, Chief Executive Officer | Buy | 250,000 | — | — |
| 2025-04-01 | PATEL, SUSHIL | Director, Chief Executive Officer | Buy | 166,667 | — | — |
| 2025-04-01 | OLIGER, CHRISTY J. | Director | Buy | 32,000 | — | — |
| 2025-04-01 | HILL, EMILY LUISA | Chief Financial Officer | Buy | 67,500 | — | — |
| 2025-04-01 | HILL, EMILY LUISA | Chief Financial Officer | Buy | 45,000 | — | — |
| 2025-04-01 | DHINGRA, KAPIL | Director | Buy | 32,000 | — | — |
| 2025-04-01 | BALACHANDRAN, MADHAVAN | Director | Buy | 32,000 | — | — |
| 2025-03-05 | BAKER, BROS. ADVISORS LP | Director, 10% Owner | Buy | 64,000 | — | — |
| 2024-12-16 | PATEL, SUSHIL | Director, Chief Executive Officer | Sale | 10,000 | $12.42 | $124200.00 |
| 2024-11-18 | XYNOS, KONSTANTINOS | Chief Medical Officer | Sale | 7,246 | $10.78 | $78111.88 |
| 2024-11-18 | SARCHI, CHRISTOPHER | Chief Commercial Officer | Sale | 5,207 | $10.78 | $56131.46 |
| 2024-09-04 | BALACHANDRAN, MADHAVAN | Director | Buy | 64,000 | — | — |
| 2024-08-30 | ASTLEY-SPARKE, PHILIP | Director, Executive Chairman | Sale | 50,000 | — | — |
| 2024-08-16 | HILL, EMILY LUISA | Chief Financial Officer | Sale | 8,938 | $10.18 | $90988.84 |
| 2024-06-07 | XYNOS, KONSTANTINOS | Chief Medical Officer | Sale | 15,881 | $7.50 | $119107.50 |
| 2024-05-16 | XYNOS, KONSTANTINOS | Chief Medical Officer | Sale | 6,367 | $6.47 | $41194.49 |
| 2024-05-16 | SCHWENDENMAN, ANDREW | Chief Accounting Officer | Sale | 2,298 | $6.47 | $14868.06 |
| 2024-05-16 | SARCHI, CHRISTOPHER | Chief Commercial Officer | Sale | 2,218 | $6.47 | $14350.46 |
| 2024-05-16 | PATEL, SUSHIL | Director, Chief Executive Officer | Sale | 20,194 | $6.47 | $130655.18 |
| 2024-05-16 | LOVE, COLIN | Chief Operating Officer | Sale | 17,615 | $6.47 | $113969.05 |
| 2024-05-16 | COFFIN, ROBERT | Director | Sale | 11,464 | $6.47 | $74172.08 |
| 2024-05-16 | ASTLEY-SPARKE, PHILIP | Director, Executive Chairman | Sale | 37,928 | $6.47 | $245394.16 |
| 2024-04-01 | XYNOS, KONSTANTINOS | Chief Medical Officer | Buy | 80,000 | — | — |
| 2024-04-01 | XYNOS, KONSTANTINOS | Chief Medical Officer | Buy | 26,665 | — | — |
| 2024-04-01 | WEINAND, DIETER | Director | Buy | 32,000 | — | — |
| 2024-04-01 | SLATTERY, JOSEPH P | Director | Buy | 32,000 | — | — |
| 2024-04-01 | SCHWENDENMAN, ANDREW | Chief Accounting Officer | Buy | 53,325 | — | — |
| 2024-04-01 | SCHWENDENMAN, ANDREW | Chief Accounting Officer | Buy | 17,775 | — | — |
| 2024-04-01 | SARCHI, CHRISTOPHER | Chief Commercial Officer | Buy | 66,675 | — | — |
| 2024-04-01 | SARCHI, CHRISTOPHER | Chief Commercial Officer | Buy | 22,225 | — | — |
| 2024-04-01 | PUCCI, PAOLO | Director | Buy | 32,000 | — | — |
| 2024-04-01 | PEEPLES-DYER, VELEKA | Director | Buy | 32,000 | — | — |
| 2024-04-01 | PATEL, SUSHIL | Director, Chief Executive Officer | Buy | 250,000 | — | — |
| 2024-04-01 | PATEL, SUSHIL | Director, Chief Executive Officer | Buy | 83,335 | — | — |
| 2024-04-01 | OLIGER, CHRISTY J. | Director | Buy | 32,000 | — | — |
| 2024-04-01 | LEVITSKY, HYAM | Director | Buy | 32,000 | — | — |
| 2024-04-01 | HILL, EMILY LUISA | Chief Financial Officer | Buy | 80,000 | — | — |
| 2024-04-01 | HILL, EMILY LUISA | Chief Financial Officer | Buy | 26,665 | — | — |
| 2024-04-01 | DHINGRA, KAPIL | Director | Buy | 32,000 | — | — |
| 2023-11-16 | XYNOS, KONSTANTINOS | Chief Medical Officer | Sale | 7,313 | $10.92 | $79857.96 |
| 2023-11-16 | SARCHI, CHRISTOPHER | Chief Commercial Officer | Sale | 5,255 | $10.92 | $57384.60 |
| 2023-09-18 | HILL, EMILY LUISA | Chief Financial Officer | Buy | 125,000 | — | — |
| 2023-09-18 | HILL, EMILY LUISA | Chief Financial Officer | Buy | 83,330 | — | — |
| 2023-09-12 | ESPOSITO, PAMELA | Chief Business Officer | Sale | 300 | — | — |
Frequently asked questions
Are REPL insiders buying or selling?
Over the transactions on record, REPL insiders have been net buyers, with about $2.75M in stock sold across 38 sales, against 1 open-market purchase.
Does insider selling at REPL mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which REPL insiders are selling the most?
Recent selling is concentrated in a few names. PATEL, SUSHIL accounts for the largest share on record, with about $758107.40 sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.